Search details
1.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-32955174
2.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Article
in English
| MEDLINE | ID: mdl-32343890
3.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
J Urol
; 210(2): 299-311, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37126069
4.
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
J Urol
; 205(2): 554-560, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33090917
5.
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Invest New Drugs
; 39(3): 812-820, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33409898
6.
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
J Urol
; 203(4): 743-750, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-31580749
7.
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Cancer
; 124(6): 1216-1224, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-29266182
8.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
J Urol
; 210(3): 411-412, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37350185
9.
Reply by Authors.
J Urol
; 210(2): 310-311, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37416959
10.
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
Int J Cancer
; 136(8): 1856-62, 2015 Apr 15.
Article
in English
| MEDLINE | ID: mdl-25219358
11.
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.
Cancer
; 121(17): 2942-50, 2015 Sep 01.
Article
in English
| MEDLINE | ID: mdl-25989179
12.
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Cancer
; 120(17): 2684-93, 2014 Sep 01.
Article
in English
| MEDLINE | ID: mdl-24802654
13.
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Lancet Oncol
; 14(9): 893-900, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23871417
14.
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Eur Urol
; 85(2): 171-176, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37085425
15.
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Prostate Cancer Prostatic Dis
; 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-38424319
16.
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
Invest New Drugs
; 31(4): 986-1000, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23397498
17.
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Anticancer Drugs
; 24(7): 743-53, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23652277
18.
Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials.
Cancers (Basel)
; 15(3)2023 Jan 23.
Article
in English
| MEDLINE | ID: mdl-36765659
19.
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw
; 10(9): 1081-7, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22956807
20.
Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation.
Int J Radiat Oncol Biol Phys
; 114(4): 705-710, 2022 11 15.
Article
in English
| MEDLINE | ID: mdl-35803445